AKT1 and cancer: Additionally, IVM augmented the anti-cancer efficacy of cisplatin in ovarian cancer, both in vitro and in vivo models, by inhibiting the Akt/mTOR pathway, thus blocking downstream signaling required for cancer cell proliferation and survival [22].